CY1115104T1 - Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας - Google Patents

Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας

Info

Publication number
CY1115104T1
CY1115104T1 CY20141100366T CY141100366T CY1115104T1 CY 1115104 T1 CY1115104 T1 CY 1115104T1 CY 20141100366 T CY20141100366 T CY 20141100366T CY 141100366 T CY141100366 T CY 141100366T CY 1115104 T1 CY1115104 T1 CY 1115104T1
Authority
CY
Cyprus
Prior art keywords
botulinum toxin
patient
headache
headphone
medicines
Prior art date
Application number
CY20141100366T
Other languages
English (en)
Inventor
Catherine C Turkel
Mitchell F Brin
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/789,180 external-priority patent/US9078892B2/en
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1115104T1 publication Critical patent/CY1115104T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μία διαταραχή κατάχρησης βραχυχρόνιων φαρμάκων πόνου (όπως μία διαταραχή κεφαλαλγίας κατάχρησης φαρμάκων) είναι δυνατόν να υποβληθεί σε θεραπευτική αγωγή δια χορήγησης αλλαντικής τοξίνης εις έναν ασθενή. Μία κεφαλαλγία είναι δυνατόν να υποβληθεί σε θεραπευτική αγωγή πλέον αποτελεσματικά δια συγχορήγησης αλλαντικής τοξίνης και μίας δραστικής ουσίας τριπτάνης εις έναν ασθενή και/ή η αποτελεσματικότητα του φαρμάκου τριπτάνης είναι δυνατόν να αυξηθεί. Η αλλαντική τοξίνη μπορεί να είναι αλλαντική τοξίνη τύπου Α και η αλλαντική τοξίνη είναι δυνατόν να χορηγείται εις το σημείο ή πλησίον αυτού, όπου ο ασθενής αισθάνεται ή έχει την προδιάθεση να αισθάνεται πόνο ή κεφαλαλγία.
CY20141100366T 2004-02-26 2014-05-23 Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας CY1115104T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/789,180 US9078892B2 (en) 2004-02-26 2004-02-26 Methods for treating pain and for treating a medication overuse disorder
US11/039,506 US20050191321A1 (en) 2004-02-26 2005-01-18 Methods for treating headache
EP05723092.2A EP1725253B1 (en) 2004-02-26 2005-02-15 Medicaments and methods for treating headache

Publications (1)

Publication Number Publication Date
CY1115104T1 true CY1115104T1 (el) 2016-12-14

Family

ID=34914767

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100366T CY1115104T1 (el) 2004-02-26 2014-05-23 Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας

Country Status (17)

Country Link
US (10) US20050191321A1 (el)
EP (3) EP2433643B1 (el)
JP (1) JP4913721B2 (el)
KR (1) KR20060126793A (el)
CN (1) CN103251937B (el)
AU (2) AU2005216887A1 (el)
BR (1) BRPI0508231A (el)
CA (2) CA2982313A1 (el)
CY (1) CY1115104T1 (el)
DK (1) DK1725253T3 (el)
ES (1) ES2460731T3 (el)
HK (2) HK1098072A1 (el)
MX (1) MX337511B (el)
PL (1) PL1725253T3 (el)
PT (1) PT1725253E (el)
SI (1) SI1725253T1 (el)
WO (1) WO2005082339A2 (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7223234B2 (en) * 2004-07-10 2007-05-29 Monitrix, Inc. Apparatus for determining association variables
WO2006078588A2 (en) * 2005-01-18 2006-07-27 Allergan, Inc. Improved methods for treating headache
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080103546A1 (en) * 2006-10-27 2008-05-01 Cyberonics, Inc. Patient management system for treating epilepsy using an implantable medical device
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
CN103813802A (zh) * 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US8420106B1 (en) 2012-03-12 2013-04-16 William J. Binder Extramuscular treatment of traumatic-induced migraine headache
ES2759478T3 (es) 2012-03-12 2020-05-11 William J Binder Tratamiento de las cefaleas por migraña con neurotoxina presináptica
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
MX356343B (es) 2012-04-13 2018-05-23 Lubrizol Advanced Mat Inc Compuestos que inhiben la exocitosis neuronal (ii).
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2919807B1 (en) * 2012-11-16 2018-07-11 Finzi, Eric Treatment of post-traumatic stress disorder using botulinum toxin a
CA2907800A1 (en) 2013-03-22 2014-09-25 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9254314B2 (en) 2013-11-12 2016-02-09 Eric Finzi Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2016149092A1 (en) 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins
CN109803673A (zh) 2016-09-13 2019-05-24 阿勒根公司 非蛋白质梭菌毒素组合物
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
WO2018175696A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
AU2018290765A1 (en) * 2017-06-26 2020-01-23 Bonti, Inc. Clostridial neurotoxin formulations and use
AU2021240083A1 (en) * 2020-03-18 2022-10-20 Revance Therapeutics, Inc. Injectable botulinum toxin methods for treating headaches

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP0770395B1 (en) * 1993-12-28 2001-10-24 Allergan Sales, Inc. Use of botulinum toxins for treating tension headache
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5670181A (en) * 1995-10-20 1997-09-23 Stokes; Christine P. Apparatus and method for slip casting for ceramic objects
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
CA2347828A1 (en) * 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
WO2001058472A2 (en) * 2000-02-08 2001-08-16 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
AU2002355730B2 (en) 2001-07-27 2007-09-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
WO2003073994A2 (en) * 2002-03-01 2003-09-12 Elan Pharmaceuticals, Inc. Methods of treating nerve entrapment syndromes
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
ZA200506715B (en) * 2003-03-06 2007-05-30 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
TWI282083B (en) * 2005-05-27 2007-06-01 Innolux Display Corp Backlight on/off control circuit
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
EP2056800B1 (en) * 2005-08-26 2015-12-09 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
CA2823974A1 (en) * 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
US8940308B2 (en) * 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
CN103813802A (zh) * 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US8420106B1 (en) * 2012-03-12 2013-04-16 William J. Binder Extramuscular treatment of traumatic-induced migraine headache
US10201487B2 (en) * 2012-04-03 2019-02-12 Basf Se Hair cosmetic composition which comprises a plant lecithin
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014123618A1 (en) * 2013-02-06 2014-08-14 Agilent Technologies, Inc. Fluidic coupling devices, assemblies, and related methods
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
EP3137053B1 (en) * 2014-04-30 2020-06-17 Allergan, Inc. Formulations of biologics for intravesical instillation
EP3191118A1 (en) * 2014-09-12 2017-07-19 Allergan, Inc. Methods for treating osteoarthritis pain
WO2016149092A1 (en) * 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins

Also Published As

Publication number Publication date
US20170128552A1 (en) 2017-05-11
AU2011201107B2 (en) 2012-12-20
US20200230217A1 (en) 2020-07-23
MX337511B (es) 2016-03-09
HK1098072A1 (en) 2007-07-13
WO2005082339A3 (en) 2005-12-01
EP2752197B1 (en) 2019-11-20
US20060121057A1 (en) 2006-06-08
DK1725253T3 (da) 2014-07-07
US8889151B2 (en) 2014-11-18
SI1725253T1 (sl) 2014-05-30
CA2982313A1 (en) 2005-09-09
US20050191321A1 (en) 2005-09-01
AU2011201107A1 (en) 2011-04-07
WO2005082339A2 (en) 2005-09-09
US20220088157A1 (en) 2022-03-24
EP1725253B1 (en) 2014-04-09
PL1725253T3 (pl) 2014-08-29
US20100189655A1 (en) 2010-07-29
CN103251937A (zh) 2013-08-21
EP2433643B1 (en) 2015-12-02
JP2007525505A (ja) 2007-09-06
US10603366B2 (en) 2020-03-31
US9555085B2 (en) 2017-01-31
US10092631B2 (en) 2018-10-09
ES2460731T3 (es) 2014-05-14
JP4913721B2 (ja) 2012-04-11
US20060104995A1 (en) 2006-05-18
KR20060126793A (ko) 2006-12-08
CA2557588C (en) 2017-11-28
US9078893B2 (en) 2015-07-14
US7704511B2 (en) 2010-04-27
PT1725253E (pt) 2014-05-06
US20190038726A1 (en) 2019-02-07
EP2752197A1 (en) 2014-07-09
AU2005216887A1 (en) 2005-09-09
EP1725253A2 (en) 2006-11-29
BRPI0508231A (pt) 2007-07-17
US20090263426A1 (en) 2009-10-22
US20150313974A1 (en) 2015-11-05
CN103251937B (zh) 2015-10-07
HK1199403A1 (en) 2015-07-03
EP2433643A1 (en) 2012-03-28
CA2557588A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
CY1115104T1 (el) Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1108436T1 (el) Χορηγηση καψαϊκινοειδων
ES2177084T3 (es) Uso de derivados de benzohidrilo sulfinilo para tratar la somnolencia de origen medicamentoso.
ATE531365T1 (de) Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
CY1108384T1 (el) Διαδερμικη δοσολογια βουπρενορφινης για αναλγησια
ATE463249T1 (de) Pharmazeutische formulierungen von kalium-atp- kanalöffnern und deren verwendungen
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
CY1115544T1 (el) Σκευασμα καψουλων πιρφενιδονης και αποδεκτων φαρμακευτικως εκδοχων
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
EA202091999A2 (ru) Применение ингибиторов dpp iv
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
ATE529113T1 (de) Salze von kalium-atp-kanal-öffnern und ihre verwendungen
GB2467691A (en) Methods for stratifying and annotating cancer drug treatment options
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
NO20032027L (no) Effektive antitumorbehandlinger
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
DE60330914D1 (de) Arzneimittel mit shikonin als wirkstoff
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
Amorim et al. Enthusiastic claims for open-label placebo pills ignore the evidence
Arnstein The future of topical analgesics